MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible series c...
$950,099
Net cash provided by
financing activities
$965,099
Net increase
(decrease) in cash
-$41,500
Canceled cashflow
$965,099
Amortization of prepaid stock
based expenses
$2,471,762
Prepaid expenses
-$333,739
Amortization of debt
discounts
$35,875
Accrued interest
$22,151
Foreign currency
transaction loss (gain)
-$19,497
Employee benefit
liability
$11,549
Accrued expenses and
other payables
$9,816
Issuance of common stock
for services
$7,500
Amortization of right-of-use
assets
$5,803
Non-cash interest
expense
$937
Depreciation expense
$229
Net cash used in
operating activities
-$999,140
Canceled cashflow
$2,918,858
Effect of exchange rate
changes on cash
-$5,192
Net cash used in
investing activities
-$2,267
Net loss
-$3,091,394
Change in fair value of
warrant liability
-$593,710
Accounts payable
-$123,564
Change in fair value of
derivative liabilities
$87,728
Loss (gain) on
extinguishment of debt, net
$14,317
Gst receivable
$8,572
Purchase of equipment
$2,267
Back
Back
Cash Flow
source: myfinsight.com
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)